Intrinsiqq
Repligen Corporation logo

Repligen Corporation Financials

RGEN

⊜ Compare

All currency values in $ millions unless otherwise noted

Scroll

Showing 6 of 18 available years
Income Statement
TTM
DEC 2025
DEC 2024
DEC 2023
DEC 2022
DEC 2021
Revenues
Revenue$806$738$634$632$802$671
Cost of Revenue$375$352$360$354$346$279
Gross Profit$431$386$275$278$456$391
General & Administrative$312$291$263$219$216$184
Research & Development$57$54$43$43$44$34
Provision for Doubtful Accounts––$0-$1-$0-$1
Total Operating Expenses$787$683$670$585$577$503
Operating Income$18$55-$35$48$225$167
Non-Operating
Net Interest Expense$4$6$15$22$6-$11
Other Non-Operating Income (Expense)-$14$1-$7-$13-$11-$3
EBT (Earnings Before Tax)$8$62-$27$57$219$154
Income Tax Expense$20$13-$2$21$33$25
Net Income
Net Income-$12$49-$26$36$186$128
Per Share Data
Revenue Per Share$14.24$13.05$11.34$11.22$13.95$11.71
EPS (Basic)-$0.20$0.87-$0.46$0.64$3.35$2.33
EPS (Diluted)-$0.20$0.86-$0.46$0.63$3.24$2.24
Weighted Avg Shares (Basic)56.6M56,23455,93755,72055,46055,015
Weighted Avg Shares (Diluted)56.6M56,56155,93756,37757,45557,264
Shares Outstanding56.6M56.6M55.9M56.4M57.5M57.3M

Repligen (RGEN) financials: revenue, profit and margins

Repligen (RGEN) generated about $806 million in revenue and -$12 million in net income (a -1.5% net margin) over the trailing twelve months, growing at roughly 15.0% a year. Figures are from SEC filings; this is analysis, not investment advice.

Frequently asked

What is Repligen's (RGEN) revenue?+

Repligen generated about $806 million in revenue over the trailing twelve months. Revenue has grown at roughly 15.0% a year over the past five years. Revenue is the top line, before any costs; what matters for value is how much of it survives to free cash flow. The full income statement, balance sheet and cash-flow statement are on this tab.

Is Repligen profitable?+

Repligen reported about -$12 million in net loss over the trailing twelve months, a net margin of roughly -1.5%. Net income is the bottom line after all costs, interest and taxes. Compare it to free cash flow on this tab, since reported profit and actual cash generated can diverge.

What are Repligen's profit margins?+

Repligen runs a gross margin of about 53.5%, an operating margin of about 2.3%, a net margin of about -1.5%. Margins show how much of each sales dollar a company keeps at each stage. Stable or rising margins usually signal pricing power and cost discipline; falling margins are worth investigating. See the multi-year trend on this tab.

How fast is Repligen growing?+

Repligen's revenue has compounded at roughly 15.0% a year over the past five years. Growth only creates value when it is profitable and cash-generative, so read this rate alongside RGEN's margins and free cash flow. This is analysis from SEC filings, not investment advice.

How the market compares: How many US companies are profitable

SourceFinancial statements computed from the 10-Q filed 23 Oct 2026, covering the period ending 30 Sept 2026, as reported to the SEC. Data last refreshed 31 Oct 2026. How this is calculated.

Fiscal year ends Dec.

Peers

Biological Products, (No Diagnostic Substances) · Pick stocks to compare with RGEN

CompareIntrinsic value
BCRXBioCryst Pharmaceuticals Inc.
$8.24-3.85%64
TARSTarsus Pharmaceuticals Inc.
$69.07-4.91%55
ADMAAdma Biologics Inc.
$10.48-5.67%82
KRYSKrystal Biotech Inc.
$310.84+1.90%44
TWSTTwist Bioscience Corporation
$142.58+1.63%40
IMCRImmunocore Holdings plc
$29.23-2.66%40
NVAXNovavax Inc.
$10.65+10.02%10
MGTXMeiraGTx Holdings plc
$9.42-1.05%74

Held by ETFs

RGEN is in 122 US ETFs. The largest of them, with RGEN's weight in each:

Spot a number that looks wrong? Check it in RGEN's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing RGEN

Create a free account and get 14 days of Premium: every stock and every tool.

  • Unlimited stocks
  • Stock screener
  • Portfolio tracker
  • Editable DCF
  • Compare side by side
  • Unlimited alerts

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.

SectorsPrivacyTerms© 2026 Intrinsiqq

Not financial advice. Analytical data for research only.

Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.